A detailed history of Marshall Wace, LLP transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Marshall Wace, LLP holds 793,839 shares of ATAI stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
793,839
Previous 775,889 2.31%
Holding current value
$1.03 Million
Previous $1.09 Million 42.87%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.5 - $2.19 $26,925 - $39,310
17,950 Added 2.31%
793,839 $1.56 Million
Q4 2023

Feb 14, 2024

BUY
$1.04 - $1.55 $806,924 - $1.2 Million
775,889 New
775,889 $1.09 Million
Q3 2022

Nov 14, 2022

BUY
$3.14 - $4.87 $137,949 - $213,953
43,933 New
43,933 $147,000
Q1 2022

May 16, 2022

SELL
$4.66 - $7.66 $1.89 Million - $3.11 Million
-406,618 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$6.82 - $17.8 $2.77 Million - $7.24 Million
406,618 New
406,618 $3.1 Million

Others Institutions Holding ATAI

About ATAI Life Sciences N.V.


  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $216M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.